These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29627316)

  • 1. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
    Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
    Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
    Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
    J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC).
    Azad AK; Qiu X; Boyd K; Kuang Q; Emami M; Perera N; Palepu P; Patel D; Chen Z; Cheng D; Feld R; Leighl NB; Shepherd FA; Tsao MS; Xu W; Liu G; Cuffe S
    Lung Cancer; 2014 Jun; 84(3):289-94. PubMed ID: 24679952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
    Kanaji N; Sakai K; Ueda Y; Miyawaki H; Ishii T; Watanabe N; Kita N; Kadota K; Kadowaki N; Bandoh S
    Lung Cancer; 2017 Jun; 108():126-133. PubMed ID: 28625624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
    Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
    Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
    Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation.
    Barquín M; Calvo V; García-García F; Nuñez B; Sánchez-Herrero E; Serna-Blasco R; Auglytė M; Carcereny E; Rodriguez-Abreu D; López Castro R; Guirado M; Camps C; Bosch-Barrera J; Massuti B; Ortega AL; Del Barco E; Gonzalez-Larriba JL; Aguiar D; García-Campelo R; Dómine M; Agraso S; Sala MA; Oramas J; Bernabé R; Blanco R; Parejo C; Cruz A; Menasalvas E; Royuela A; Romero A; Provencio M
    Cancer Epidemiol; 2020 Aug; 67():101737. PubMed ID: 32450544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell Lung Cancer.
    Lei L; Jiang ZM; Li CH; Lu HY
    Curr Med Sci; 2019 Jun; 39(3):379-384. PubMed ID: 31209806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
    Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
    Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: impact on survival outcome.
    Elsamany SA; Al-Fayea TM; Alzahrani AS; Abozeed WN; Darwish W; Farooq MU; Almadani AS; Bukhari EA
    Asian Pac J Cancer Prev; 2015; 16(7):2987-91. PubMed ID: 25854394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.